Navigation Links
REXIN-G Shrinks Metastatic Tumors and Triples Survival Time in Chemotherapy-Resistant Pancreatic Cancer: Analysis of a U.S. Phase I/II Clinical Trial (Proceedings of ASCO GI Symposium 2009)
Date:1/20/2009

SAN MARINO, Calif., Jan. 20 /PRNewswire/ -- Epeius Biotechnologies (www.epeiusbiotech.com) announced the results of a U.S. Phase I/II study evaluating the safety and efficacy of Rexin-G in chemotherapy-resistant metastatic pancreatic cancer (ASCO GI Symposium, #249; Sant P Chawla, P.I., Santa Monica CA, January 2009). Rexin-G was well tolerated and there was no dose-limiting toxicity. At Dose Level I, three patients achieved stable disease with no tumor progression; and at Dose Level II, one patient had a 37% decrease in tumor size and five patients exhibited disease stabilization with no tumor progression. Importantly, Rexin-G improved patient survival in a dose-dependent manner: At Dose Level I, median progression-free survival was 3 months, and median over-all survival was 5 months, while at Dose Level II, median progression-free survival was greater than 3 months, and median over-all survival was greater than 9 months.

By direct comparison with a prior low-dose Phase I safety study (Galanis et al. 2008), the new "effective doses" of Rexin-G nearly tripled the overall survival time. Thus, this current Phase I/II study defines a critical pharmacological "threshold" for Rexin-G bioactivity in the treatment of metastatic pancreatic cancer. The present study confirms the overall safety of Rexin-G, and further demonstrates that Rexin-G monotherapy, at these defined dose levels, exhibits profound anti-tumor activity that prolongs both progression-free survival and over-all survival time in pancreatic cancer patients that had previously failed standard chemotherapy.

Rexin-G is the world's first and so far only targeted injectable genetic medicine that has been validated in the clinic (Nature Reviews/Genetics 2007). Injected intravenously, the targeted nanoparticles are designed to seek out and destroy both primary tumors and metastatic cancers that have spread t
'/>"/>

SOURCE Epeius Bio
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. ASCO 2008: Tumor-Targeted Rexin-G Demonstrates Dose-Dependent Anti-Tumor Activity Without Toxicity in Metastatic Pancreatic Cancer
2. Epeius Biotechnologies Tumor-Targeted Rexin-G Receives FDA Orphan Drug Designation for the Treatment of Osteosarcoma
3. FDA Grants Epeius Biotechnologies Rexin-G a Third Orphan Drug Designation, This Time for the Treatment of Soft Tissue Sarcomas
4. Epeius Biotechnologies Lead Product, Rexin-G for Metastatic Cancer, Aptly Highlighted by National Cancer Institute Journal
5. Rexin-G Returns to The Big Apple: Clinical Trials for Pancreatic Cancer and Breast Cancer Open in Manhattan
6. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
7. Center for Molecular Medicine One of the First Midwest Labs to Offer Advanced Test for Patients with Metastatic Breast Cancer
8. Kosans Hsp90 Inhibitor, Tanespimycin, Shows 55% Clinical Benefit in Patients With Trastuzumab-Refractory Metastatic Breast Cancer
9. Accelerated Community Oncology Research Network, Inc. (ACORN), Initiates a Phase 2b Metastatic Breast Cancer Trial in Cooperation With Bayer and Onyx
10. Oncothyreon initiates Phase 1b trial of PX-12 in patients with advanced metastatic cancer
11. NOTICE OF YM BIOSCIENCES CONFERENCE CALL TO DISCUSS PHASE II DATA FOR NIMOTUZUMAB IN METASTATIC COLORECTAL CANCER
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... Scottsdale, AZ (PRWEB) July 11, 2014 ... medicine device company specializing in the soft tissue ... SureLock All-Suture Anchor System for surgeries involving the ... predictable fixation through a novel, inserter-controlled deployment method. ... lead to partial deployment, anchor pull-out, or anchor ...
(Date:7/10/2014)... 2014 Product and process impurities ... abundance and are often “lost in the noise,” ... Join presenters Dr. Rowel Tobias, Senior Scientist, Protein ... Head of Quality at Nanotherapeutics, Inc., to lear ... speed detection and quantitation while achieving the required ...
(Date:7/10/2014)... Understanding the need for better quality ... the gap that currently exists in this area, ChanTest ... portfolio of validated ion channel and GPCR cell lines. ... as ion channels control many critical physiological functions throughout ... the potential to treat a variety of human diseases. ...
(Date:7/10/2014)... Francisco, CA (PRWEB) July 10, 2014 ... family closer together. The Archer Family purchased a ... contained within DNA, but ended up with a lifetime ... discoveries contained within the family members’ DNA genuinely brought ... had decided to search deeper into genetic history and ...
Breaking Biology Technology:Cayenne Medical Launches SureLock™ All-Suture Anchor System for Shoulder and Extremity Surgery 2Cayenne Medical Launches SureLock™ All-Suture Anchor System for Shoulder and Extremity Surgery 3Novel Ms Techniques Speed Detection of Biopharmaceutical Product and Process Impurities, New Webinar Hosted by Xtalks 2Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 2Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 3Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 2Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 3Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 4Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 5
... Medical Incorporated (OTCBB: ONCS), which is developing its advanced-stage ... financial results for the quarter ended April 30, 2011. ... Total operating expenses for the three and nine months ... compared to $3,000 and $15,000 for the three and ...
... BioXpress Therapeutics SA, a Swiss-based biotechnology company ... ) biosimilars announced today representatives from the Company ... Convention,s One-on-One Partnering Meetings being held Jun 27-30 ... Convention Center.   BioXpress Therapeutics currently ...
... Health Care Compliance Strategies, Inc. (HCCS) , the leading ... announced the release of a new online multimedia HIPAA ... . Responding to expanded HIPAA Privacy Rule and Security ... course designed to assist healthcare vendors in providing experience-based ...
Cached Biology Technology:OncoSec Medical Reports Third Quarter 2011 Financial Results 2OncoSec Medical Reports Third Quarter 2011 Financial Results 3OncoSec Medical Reports Third Quarter 2011 Financial Results 4BioXpress Therapeutics SA to Partner the 2011 BIO International Convention 2New Online Training Course Helps Healthcare Vendors Comply with HIPAA Regulations 2New Online Training Course Helps Healthcare Vendors Comply with HIPAA Regulations 3
(Date:7/10/2014)... , July 2, 2014 It is a ... announce the appointment of the world-renowned Thoracic and Cardiovascular ... Directors. Dr. Ginsburg, with over 34 years ... Presbyterian Hospital and Good Samaritan Regional Medical Center. Dr. ... the late 1980,s and is considered an expert in ...
(Date:7/10/2014)... , July 3, 2014 Research and ... of the "Global Gesture Recognition & Touch-Less ... Forecasts to 2020" report to their offering ... Global Gesture Recognition & Touch-Less Sensing Market to ... for a while, but the companies were unable ...
(Date:7/10/2014)... 8, 2014 Fingerprint Cards, ... design win (DW). An Asian OEM has selected FPC1021 for ... start in August 2014.   FPC is proud ... has a planned date for start of mass production in ... of SEK 5M, for delivery in the first half of ...
Breaking Biology News(10 mins):Avery Biomedical Devices, Inc. announces the appointment of Mark E Ginsburg, M.D. to its Board of Directors 2Global Gesture Recognition & Touch-Less Sensing (2D, 3D, Ultrasonic, IR, Capacitive) Market - Forecasts to 2020 2FPC Wins DW and Initial Ramp Order for FPC1021 Touch Sensor for Flagship Smartphone from Asian OEM 2
... type 2 diabetes, not only do waistlines matter to women, but ... discovery by a team of Swedish researchers was just published online ... some women of normal weight develop type 2 diabetes, despite not ... between enlarged fat cells and the development of type 2 diabetes ...
... − One of the most intriguing developments in recent medical ... Since its detection in 1988, over 22,000 scholarly articles (about ... new class of drugs has been developed, and 25 Phase ... the scientific and medical communities involved in ET move towards ...
... their home and car energy use by as much as ... , They explain how in The CSIRO Home Energy Saving ... Your Carbon Footprint, launched today by Innovation Minister Senator Kim ... solution will require action from every individual," Senator Carr said. ...
Cached Biology News:Size of fat cells and waist size predict type 2 diabetes in women 2International conference on endothelin 2International conference on endothelin 3Energy experts helping Australian households reduce carbon emissions 2
... Dyad instrument is the most advanced thermal ... world-class thermal performance, the Dyad also boasts ... as point-and-click navigation via touch pad or ... easily and economically expanded to a four-bay ...
...
The sealed ice cooling unit is used to absorb heat that is generated during transfers performed in the Criterion blotter....
Printer paper for Model 680 series readers is used with the thermal printers of the Model 680 and Model 680 XR microplate readers. Supplied as 2 rolls....
Biology Products: